Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550771 | 0.86 | NR3C2 (0.57) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL23795665 | 0.85 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL30033506 | 0.84 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL20550934 | 0.83 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL20550768 | 0.82 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL21797184 | 0.81 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL28400055 | 0.80 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11BRDT | |
| SCHEMBL20550878 | 0.79 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL20551168 | 0.79 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL20550529 | 0.78 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200079757-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | THE UNIVERSITY OF MELBOURNE (AU) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079757-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | LTC4S, LTB4R2, LTB4R | MAPK14 4326/4885MAPK13 3615/4885MAPK12 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.